A Randomized Trial of Intensive versus Standard Blood-Pressure Control (SPRINT)
Source: View publication →
In high-risk adults without diabetes or a history of stroke, intensive blood pressure control targeting a systolic pressure of less than 120 mm Hg significantly reduced the rates of major cardiovascular events and death from any cause compared to a standard target of less than 140 mm Hg.
Key Findings
Study Design
Study Limitations
Clinical Significance
SPRINT represents a landmark paradigm shift in cardiovascular medicine. By demonstrating a clear mortality and morbidity benefit to aggressive blood pressure lowering in high-risk patients, it directly catalyzed the 2017 ACC/AHA guidelines, which formally redefined hypertension as a blood pressure of ≥130/80 mm Hg and lowered the treatment targets for most adults. It also highlighted the necessary clinical trade-off between preventing macrovascular events and managing increased risks of hypotensive and renal adverse effects.
Historical Context
Prior to SPRINT, the optimal systolic blood pressure target was intensely debated. Previous trials, notably the ACCORD BP trial in diabetic patients, failed to show a significant primary cardiovascular benefit for targeting a systolic pressure <120 mm Hg. Additionally, recent guidelines preceding SPRINT (such as JNC 8 in 2014) had actually relaxed blood pressure targets to <150/90 mm Hg for adults over 60, largely due to fears of the 'J-curve' phenomenon (where excessively low blood pressure might precipitate cardiovascular events). SPRINT decisively countered this trend for high-risk non-diabetic populations, proving that 'lower is better' when monitored carefully.
Guided Discussion
High-yield insights from every perspective
How does intensive systolic blood pressure lowering conceptually reduce the risk of heart failure, which was one of the primary drivers of the composite cardiovascular outcome reduction in the SPRINT trial?
Key Response
High systolic blood pressure increases left ventricular afterload, leading to concentric left ventricular hypertrophy, impaired relaxation (diastolic dysfunction), and eventually decompensated heart failure. Lowering the target to less than 120 mm Hg reduces this afterload, preventing pathological remodeling and preserving myocardial function. This highlights the direct pathophysiological link between hemodynamics and end-organ damage.
The SPRINT trial specifically excluded patients with diabetes mellitus and prior stroke. Given this exclusion, how should we approach blood pressure management for a 65-year-old patient with a history of type 2 diabetes and a current systolic BP of 135 mm Hg?
Key Response
Residents must recognize study exclusion criteria to avoid inappropriate generalization of evidence. The ACCORD-BP trial investigated intensive BP control in diabetics and did not show the same primary composite cardiovascular benefit as SPRINT, although it did reduce stroke risk. Current ACC/AHA guidelines recommend a target of less than 130/80 mm Hg for patients with diabetes, requiring a nuanced, patient-specific approach rather than blindly applying the SPRINT less than 120 mm Hg target.
SPRINT demonstrated a significant reduction in cardiovascular events but also an increased incidence of acute kidney injury (AKI) and electrolyte abnormalities in the intensive arm. How do we differentiate between hemodynamically mediated eGFR decline and true intrinsic renal injury in these aggressively treated patients?
Key Response
Fellows must balance the trade-offs of aggressive therapies. The AKI observed in SPRINT was often a reversible decline in eGFR due to reduced renal perfusion pressure secondary to RAAS blockade and aggressive diuresis, rather than structural tubular damage. Understanding this distinction is crucial for deciding whether to safely continue, adjust, or completely hold life-saving antihypertensive regimens when serum creatinine predictably rises.
The SPRINT trial utilized automated office blood pressure (AOBP) measurements, where patients were seated alone in a quiet room and multiple automated readings were averaged. How does this methodological nuance impact the safety and feasibility of translating the less than 120 mm Hg target into a busy primary care setting?
Key Response
Attendings must contextualize trial methods into real-world workflows. AOBP minimizes the white-coat effect and generally yields readings 5 to 10 mm Hg lower than traditional, often rushed, triage-nurse measurements. Attempting to achieve a less than 120 mm Hg target using standard clinical measurements might inadvertently push the patient's true resting systolic BP dangerously low, increasing the risk of iatrogenic hypotension, syncope, and falls.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The SPRINT trial was terminated early for benefit after a median follow-up of 3.26 years due to a significant reduction in mortality. What are the statistical and epidemiological risks associated with early trial termination, and how might this affect the estimated magnitude of the treatment effect?
Key Response
Trials stopped early for benefit are highly susceptible to overestimating the true treatment effect, a phenomenon known as random high bias or the winner's curse. While early stoppage was ethically justified by the data safety monitoring board, researchers must critically evaluate whether the absolute risk reduction would have regressed toward the mean with longer follow-up, and whether the truncated timeline prevented the detection of late-emerging adverse effects.
SPRINT utilized a PROBE (Prospective Randomized Open, Blinded End-point) design, meaning the intervention was open-label while end-point adjudication remained blinded. What specific threats to internal validity does this design introduce, particularly regarding the reporting of adverse events?
Key Response
In a PROBE design, both patients and treating clinicians are aware of the treatment allocation. This introduces significant detection and reporting bias. Clinicians might be more vigilant in checking for and documenting hypotensive episodes, syncope, or AKI in the intensive arm, while patients may be more likely to report side effects. A critical reviewer must scrutinize whether the safety profile was artificially skewed by this lack of blinding during the clinical encounter.
Following SPRINT, the 2017 ACC/AHA guidelines redefined hypertension and lowered the general blood pressure target to less than 130/80 mm Hg, a departure from JNC 8 recommendations. Based strictly on SPRINT, should future guidelines explicitly assign a Class I recommendation for a less than 120 mm Hg target for non-diabetic high-risk patients, or do implementation barriers preclude this?
Key Response
Guideline committees must weigh raw trial efficacy against real-world harms and measurement practicalities. While SPRINT proved less than 120 mm Hg is superior in a highly controlled environment with AOBP, assigning it a Class I recommendation universally is controversial. Committees must decide if guidelines should mandate the specific measurement technique (AOBP) alongside the aggressive target, and whether the number needed to harm regarding polypharmacy and syncope outweighs the benefits when applied broadly outside of an academic trial setting.
Clinical Landscape
Noteworthy Related Trials
ACCORD BP Trial
Tested
Intensive BP control (target systolic <120 mm Hg)
Population
Patients with type 2 diabetes at high risk for cardiovascular events
Comparator
Standard BP control (target systolic <140 mm Hg)
Endpoint
Composite of nonfatal MI, nonfatal stroke, or cardiovascular death
SPS3 Trial
Tested
Intensive BP control (target systolic <130 mm Hg)
Population
Patients with a recent symptomatic lacunar stroke
Comparator
Standard BP control (target systolic 130-149 mm Hg)
Endpoint
Recurrent stroke (ischemic or hemorrhagic)
STEP Trial
Tested
Intensive BP control (target systolic 110-130 mm Hg)
Population
Older adults (aged 60-80 years) with hypertension
Comparator
Standard BP control (target systolic 130-150 mm Hg)
Endpoint
Composite of stroke, acute coronary syndrome, decompensated heart failure, revascularization, atrial fibrillation, or CV death
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis